Drug Development
UCB and Novartis Discontinue Development of Parkinson’s Disease Drug After Phase 2 Failure
UCB, Novartis, Parkinson’s disease, drug development, Phase 2 failure, UCB0599, UCB7853
Biomarker Data’s Potential to Expedite Approval of Edgewise’s Dystrophy Drug
Biomarkers, drug development, Edgewise Therapeutics, Becker muscular dystrophy, regulatory approval
Novo Holdings to Finalize $16.5B Acquisition of Catalent Following Regulatory Clearance
Novo Holdings, Catalent, Acquisition, Regulatory Clearance, Life Sciences, Pharmaceutical Development
Relmada Therapeutics Reassesses Strategy Following Discontinuation of Two Phase 3 Trials for REL-1017
Relmada Therapeutics, REL-1017, Phase 3 trials, Major Depressive Disorder (MDD), strategic options, clinical trials, drug development
Nabla Bio Revolutionizes AI-Driven Protein Design with $26M Series A Funding and Major Pharmaceutical Collaborations
Generative Protein Design, AI-Driven Drug Development, Therapeutic Antibodies, Multipass Membrane Proteins, Pharmaceutical Collaborations, Series A Funding
AstraZeneca Halts Development of Opioid Use Disorder Drug Due to Antifungal Interaction
AstraZeneca, Opioid Use Disorder, Drug Development, Antifungal Interaction, Clinical Trials
Enveda Secures $130 Million in Funding for Innovative Therapies in Inflammation, Obesity, and Beyond
Enveda, Microsoft-backed, $130M funding, Inflammation & Immunology (I&I), obesity, biotech, pharma, drug development
Aizen Therapeutics Unveils AI-Driven ‘Mirror Peptide’ Platform to Revolutionize Drug Development
Aizen Therapeutics, Caltech spinout, AI-driven platform, mirror peptides, drug development, biologic medicine, cancer treatment
Pfizer Expands Collaboration with Flagship Pioneering, Adding Ampersand Biomedicines and Montai Therapeutics
Pfizer, Flagship Pioneering, Ampersand Biomedicines, Montai Therapeutics, strategic partnership, drug development, obesity, non-small cell lung cancer
Evotec Shares Soar as Private Equity Firm Triton Considers Takeover Bid
Evotec, Triton Partners, takeover bid, private equity, drug development, pharmaceuticals